We are thrilled to announce that AIRNA, a groundbreaking biotech company at the forefront of RNA editing therapeutics, has successfully raised $60 million in its latest funding round. This substantial investment underscores the confidence of our investors in AIRNA's mission to revolutionize treatment options for patients suffering from both rare and common diseases. With a dedicated and experienced team, AIRNA is committed to advancing its innovative pipeline of RNA editing therapeutics, powered by our cutting-edge RNA editing platform, RESTORE+. The funding will be instrumental in accelerating the development of our therapies, facilitating clinical trials, and expanding our research capabilities. Our vision is clear: to unlock the potential of RNA editing to correct genetic abnormalities and enhance patient health outcomes. This funding milestone not only fuels our ongoing research but also brings us closer to our goal of providing transformative therapies that harness the power of genetic precision. We are excited about the journey ahead and look forward to sharing our progress as we work tirelessly to make a meaningful impact in the lives of those battling challenging health conditions. Stay tuned for updates as we continue to push the boundaries of biotechnology and transform the future of medicine!
Breaking News: AIRNA Secures $60 Million in Series A Funding to Revolutionize RNA Editing Therapeutics
Recently funded · $60.0M Series aHealthcare
Get the full AIRNA company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
